The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Neurocrine Biosciences Inc in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Neurocrine Biosciences Inc.
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels
Biotech company did not disclose the reason for the partnership’s end
Drug wasn’t able to improve on placebo
Will face competition from Myovant rival
Investors concerned on how it stacks up against AbbVie rival
Company looks to migrane treatment Ajovy for growth
First new oral treatment in more than 10 years
The twice-daily drug will compete with Neurocrine Bioscience’s Ingrezza
Ingrezza edges ahead of Teva’s rival drug Austedo
Actelion, Johnson & Johnson, Sanofi, Takeda and more feature in this month’s pharma deals round-up
Could be first approved treatment for tardive dyskinesia
NBI-98854 in trials for tardive dyskinesia
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology